ERBB2 NON-AMPLIFICATION

CI-VAR-00002979Explore in graph →CIViC 1320

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HER2 Negative Breast Cancer1unmapped disease
ERBB2 NON-AMPLIFICATION	Lapatinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID3052 Women with primary breast cancer were randomized (3:1) to 10 to 14 days of preoperative lapatinib or placebo in a multicenter phase II trial. Biopsies pre-/posttreatment were analyzed for Ki67, apopto… (full text at CIViC) PMID 25398453 · Leary et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.